Proteinuria and blood pressure should be monitored regularly to evaluate the patient’s response to antihypertensive agents, and in CKD, proteinuria is a risk factor for CVD. Modification of antihypertensive treatment goals should be considered in patients with point-in-time urine protein/urine creatinine ratios greater than 500-1000 mg/g. A lower systolic target value,, initiation of antihypertensive therapy or an increase in the dose of antihypertensive medication to reduce proteinuria. Before these interventions are implemented, a nephrologist should generally be consulted Drug therapy is more likely to cause adverse drug reactions in patients with CKD than in the general population and should be monitored more frequently. Blood pressure, GFR, and potassium should be measured prior to treatment initiation and repeated within 12 weeks of treatment initiation or after a change in ACE inhibitor or ARB dose. Blood pressure, GFR and potassium should be measured within 4 weeks for patients with: 1. systolic blood pressure <120 or ≥140 mmHg 2. GFR <60 ml/min/1.73O 3. change in GFR >15% within 2 months 4. potassium >4.5 mEq/L (if using an ACE inhibitor or ARB) or <4.0 mEq/L (if using a diuretics).